Biopharma optimism climbs after FDA commissioner Makary's exit, survey finds

Endpoints Signal released its Q3 Biopharma Sentiment Index, showing the highest level of industry optimism in years, according to a survey of 569 insiders.

The index’s regulatory score rose sharply to 75, up from 50 in the previous quarter and far above the 23 recorded a year ago, indicating that concerns about the FDA environment are easing.

Executives expressed hope that stability will return now that former commissioner Marty Makary has left, though some noted that the agency still bears significant damage.